AtriCure Inc

ATRC remains in a Stage 2 uptrend with a clean, accelerating parabola, but price is deeply overbought and extended above the 9-EMA and 20-EMA. The medium-term bias is bullish; however, execution is deferred. Traders should wait for a consolidation or shallow pullback into the 9-EMA to 20-EMA zone for demand absorption before engaging.

• ↑2025 revenue $534M (+15% YoY) driven by AtriClip Flex Mini, CryoSphere Max
• ↑Pain management sales up 28% in 2025 on CryoSphere Max adoption
• ↓Negative earnings yield and weak profitability metrics signal return challenges